Sanofi: positive phase III data in IPT
(CercleFinance.com) - Sanofi announces that its Phase III LUNA 3 study of rilzabrutinib for the treatment of immune thrombocytopenia (IPT) met its primary endpoint, enabling patients to achieve a durable platelet response.
The safety profile of rilzabrutinib was consistent with that observed in previous studies. Regulatory submissions are planned in the US and the EU by the end of the year. A serious autoimmune disease, IPT is characterised by the formation of antibodies that destroy platelets, and the disruption of platelet production leading to thrombocytopenia and increased bleeding episodes. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
03/05/2024 17:36
Renaultpartenariat pluriannuel entre Alpine F1 et ApeCoin 03/05/2024 17:26 Novo Nordiskle titre recule, un analyste ajuste sa cible 03/05/2024 16:55 UMGtitre en hausse, un analyste relève sa cible 03/05/2024 16:00 ArkemaBlackRock sous les 5% du capital 03/05/2024 15:46 J&Jprésentera ses avancées dans les maladies de la rétine 03/05/2024 15:36 Nexansle titre recule, Barclays se veut prudent Tous les articles sociétés |
